Is Wall Street Underestimating Philip Morris International Stock’s Potential?
Philip Morris International (PM) stock is currently trading at an attractive valuation despite strong fundamentals, including accelerating growth in smoke-free products, high operating margins, and a low-debt structure. While the company's transition to smoke-free products like IQOS and ZYN offers significant upside, the investment debate centers on whether this growth can offset competitive and regulatory challenges, as well as recent deceleration in ZYN's growth. The article suggests that Wall Street might be underestimating PM's potential given its solid performance against sector medians.
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals
Regeneron Pharmaceuticals (REGN) is under valuation scrutiny after the FDA approved extended dosing for EYLEA HD, easing treatment schedules. Despite a 34% one-year total shareholder return, the stock's year-to-date performance is slightly negative. Simply Wall St's analysis suggests REGN is modestly undervalued at $763.04, with a fair value pegged at $873.78, though its P/E ratio is higher than the US Biotech average.
Viridian Therapeutics stock tumbles after Amgen Tepezza data
Viridian Therapeutics Inc (NASDAQ: VRDN) shares dropped 25.2% after Amgen (NASDAQ: AMGN) announced strong Phase 3 results for its TEPEZZA OBI drug, which treats Thyroid Eye Disease. While Amgen's drug showed higher efficacy in proptosis response rates compared to Viridian's elegrobart, analysts noted Viridian's treatment offers greater dosing convenience. Despite the data, several analysts maintained positive ratings and price targets for Viridian.
Under-the-skin Tepezza comparable to infused version in key study, Amgen says
Amgen has announced that an injectable, on-body injector version of its thyroid eye disease drug, Tepezza, demonstrated comparable efficacy to the infused version in a Phase 3 trial. This subcutaneous option, named Tepezza OBI, could help Amgen maintain market leadership against emerging rivals and potentially expand market access by offering a more convenient treatment. The company expects to disclose full study results at an upcoming medical meeting, with analysts noting the critical role of competitive convenience and safety profiles for market positioning.
Amgen’s Subcutaneous Tepezza Scores In TED As More Convenient Version
Amgen has announced positive topline results from its Phase III trial for a subcutaneous formulation of Tepezza, a drug used to treat Thyroid Eye Disease (TED). This new version is expected to offer a more convenient administration option for patients. The article highlights this development within the context of pharmaceutical business news.
Why Is Viridian Therapeutics Stock Sinking Monday?
Viridian Therapeutics (NASDAQ: VRDN) stock declined sharply following positive Phase 3 data from Amgen (NASDAQ: AMGN) for TEPEZZA in thyroid eye disease (TED), intensifying competitive pressure. Viridian's own REVEAL-1 trial for elegrobart met its primary endpoint but showed weaker efficacy compared to peers, leading to investor concerns about commercial viability. Despite this, Viridian plans to submit a Biologics License Application (BLA) for elegrobart in Q1 2027 and believes its pipeline candidates veligrotug and elegrobart have significant potential in the TED market.
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
Viridian Therapeutics stock plummeted after Amgen announced positive Phase 3 trial results for its new thyroid eye disease treatment. Viridian is also developing a subcutaneous treatment for the same condition, Elegrobart. The market reacted negatively to Amgen's progress, impacting Viridian's share price.
Amgen Posts 77% Response In Thyroid Eye Disease Study
Amgen's Phase 3 TEPEZZA OBI trial for moderate-to-severe active Thyroid Eye Disease met its primary endpoint, showing a 77% proptosis response rate and a mean proptosis reduction of -3.17 mm. This positive news comes despite a recent FDA warning regarding liver injuries tied to Amgen’s other drug, Tavneos. Amgen's stock is currently in a consolidation phase, with its Benzinga Edge signal indicating strong quality but weak value and neutral growth metrics, suggesting a cautious approach for investors.
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It?
Biogen acquired Apellis for $5.6 billion, representing a 140% premium, a deal met with skepticism from the market due to Apellis's flagship drug SYFOVRE experiencing a revenue decline. While SYFOVRE faces challenges, the acquisition's strategic value is bolstered by EMPAVELI, approved for rare kidney diseases, and the unpriced optionality of felzartamab, a drug in Phase 3 trials for kidney diseases. The deal was structured to be accretive to non-GAAP diluted EPS starting in 2027, with the long-term success hinging on EMPAVELI's ramp-up and a successful felzartamab readout.
Amgen (AMGN) Reveals Positive Phase 3 Results for Subcutaneous T
Amgen has announced positive Phase 3 trial results for a subcutaneous version of Tepezza, administered via an on-body injector for Thyroid Eye Disease (TED). The new formulation showed similar efficacy to the intravenous standard, achieving a 77% proptosis response rate. Despite strong revenue growth, the company faces declining margins and a high debt-to-equity ratio, with recent insider selling noted.
Amgen scores with trial of on-body injected version of Tepezza in thyroid eye disease
Amgen has found a potential way to boost sales of its thyroid eye disease (TED) treatment, Tepezza, through a new patient-friendly subcutaneous injection administered via an on-body injector (OBI). A phase 3 trial demonstrated that Tepezza OBI achieved comparable efficacy to the current intravenous (IV) formulation, meeting its primary endpoint with a 77% proptosis response rate. This new delivery method aims to increase patient convenience and accessibility for the drug, which has seen stagnant sales despite being the only approved treatment for TED.
Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD?
Gilead Sciences (GILD) stock has dropped 11% from its 52-week high, prompting investors to question if this presents a buying opportunity. The company recently made two major acquisitions, with the primary deal acquiring Arcellx for its CAR T-cell therapy anito-cel, awaiting FDA approval. Despite an expanded balance sheet, a strong HIV franchise, and multiple upcoming commercial launches targeted for 2026, the company faces risks like potential delays in drug approvals and impacts from the Inflation Reduction Act on Biktarvy's revenue.
Genome Editing Market Is Going to Boom |• CRISPR Therapeutics • Editas Medicine
Worldwide Market Reports has published a comprehensive analysis titled "Genome Editing Market Size and Forecast 2026-2033," predicting significant growth in the genome editing sector. The report, based on extensive research, details market drivers, challenges, opportunities, and competitive landscapes, featuring key players like CRISPR Therapeutics and Editas Medicine. It offers crucial insights for stakeholders, covering market segmentation by types and applications, regional trends, and forecasts to aid investment decisions.
Breast to lung cancers: IDEAYA puts IDE574 into human testing
IDEAYA Biosciences announced the first patient enrolled in its Phase 1 trial for IDE574, a potential first-in-class dual inhibitor of KAT6 and KAT7. This oral therapy targets solid tumors including breast, prostate, colorectal, and lung cancer, aiming for monotherapy efficacy and durable anti-tumor responses. Preclinical data show high potency and selectivity, with further details to be presented at AACR 2026.
Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks
Amgen is strategically shifting its focus toward next-generation drugs like the obesity candidate MariTide to counteract the impact of biosimilar competition on its legacy products. The company aims for sales between $37-38.4 billion by 2026, balancing existing cash cows with new pipeline bets in areas such as obesity and oncology. Despite risks from biosimilars and pipeline execution, analysts generally view Amgen's long-term positioning positively, supported by its dividend strength and robust margins.
Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks
Amgen Inc. is strategically pivoting its pipeline to achieve $37-38.4 billion in sales by 2026, driven by next-generation drugs like the obesity candidate MariTide. This move is crucial for counteracting biosimilar erosion on its legacy products and positions Amgen as a resilient biotech play with strong dividend potential for global investors. The company aims to balance mature cash cows with innovative treatments in key areas like obesity and oncology, while maintaining robust financial health and attractive margins.
Capricorn Fund Managers Ltd Invests $4.12 Million in Pfizer Inc. $PFE
Capricorn Fund Managers Ltd recently invested $4.12 million to acquire a new stake of 165,569 shares in Pfizer Inc. during the fourth quarter. This move comes as Pfizer reported strong Q4 results, surpassing analyst expectations with $0.66 EPS and $17.56 billion in revenue, despite a slight year-over-year revenue decrease. Institutional investors collectively own a significant portion of Pfizer, holding about 68.36% of the company's stock, while analysts currently maintain an average "Hold" rating with a target price of $28.19.
Buffalo Business & Estate Services Ltd. Takes Position in Amgen Inc. $AMGN
Buffalo Business & Estate Services Ltd. has acquired 16,716 shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, valued at approximately $5.47 million, making it their 21st largest holding. Amgen recently reported strong Q4 earnings, beating analyst expectations with $5.29 EPS and $9.87 billion in revenue, and announced a quarterly dividend of $2.52 per share. Institutional investors now own 76.5% of the company's stock, and analysts have a consensus "Hold" rating with an average target price of $354.60.
Antibodies Market To Witness Substantial Growth, 2026-2033 | Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc.
The Antibodies Market is projected to experience substantial growth,
Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed?
Precigen (PGEN) experienced a 7.4% stock increase after reporting a significant rise in 2025 revenue to US$9.68 million, alongside a widened net loss of US$250.64 million. This article examines how these results, particularly the substantial net loss, impact the investment outlook for Precigen and its primary therapy, PAPZIMEOS. While revenue growth is encouraging, the increased losses highlight the importance of successful commercialization and raise concerns about short-term dilution and financing risks.
A Look At Zai Lab (ZLAB) Valuation After New Amgen Oncology Collaboration News
Zai Lab (ZLAB) has entered a global clinical trial collaboration with Amgen for DLL3-targeting therapies, boosting its short-term stock momentum. Despite recent gains, long-term holders have seen declines, but analysts consider the stock 58.8% undervalued given significant projected revenue growth and increased profit margins over the next three years. However, risks include reliance on in-licensed assets and competition in China.
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh Trade Ideas — BMFBOVESPA:AMGN34
This page on TradingView for Amgen Inc. (AMGN34) aggregates various trade ideas and analyses from different traders. These ideas range from cautious sentiments on new drug approvals and earnings to bullish predictions based on long-term support and innovative product pipelines, as well as bearish outlooks citing technical patterns like double tops and downtrends. The content covers financial insights, analyst ratings, and technical analysis perspectives on the stock.
A Look At Amgen (AMGN) Valuation After New Repatha Data And Zai Lab Oncology Collaboration
Amgen (AMGN) is gaining attention due to new Repatha data for high-risk diabetes patients and an oncology collaboration with Zai Lab. Despite recent share price cooling, its long-term returns remain strong, trading just below analyst targets. The company's valuation, however, presents a mixed picture of being undervalued with potential for growth but also facing pressure from drug pricing reforms and biosimilar competition.
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer
Zai Lab Limited and Amgen Inc. have announced a global clinical trial collaboration to investigate a combination therapy for extensive-stage small cell lung cancer (ES-SCLC). The study will evaluate Zai Lab’s DLL3-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan, with Amgen’s IMDELLTRA®, a DLL3-targeting Bispecific T-cell Engager therapy. Amgen will lead and sponsor the global Phase 1b study, with Zai Lab retaining full ownership of zocilurtatug pelitecan.
PJP Stock News Today | Earnings, Events & Price Alerts
This page provides news and events related to PJP stock, including articles discussing the pharmaceutical industry, PBMs, and the impact of potential government policies. Notable headlines cover concerns about the US pharmaceutical industry's competition with China, the performance of pharma ETFs, and criticisms of PBM practices by Eli Lilly's CEO. The page also features an overview of PJP's stock performance and related financial tools from Intellectia.AI.
Thurston Springer Miller Herd & Titak Inc. Acquires 3,354 Shares of Amgen Inc. $AMGN
Thurston Springer Miller Herd & Titak Inc. increased its stake in Amgen Inc. by 464.5% in the fourth quarter, acquiring an additional 3,354 shares to own a total of 4,076 shares valued at $1,334,000. Other institutional investors also adjusted their positions in Amgen, which reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $2.52 per share. Analyst ratings for Amgen are generally positive, with an average "Hold" rating and an average target price of $354.60.
SteelPeak Wealth LLC Has $37.88 Million Holdings in Amgen Inc. $AMGN
SteelPeak Wealth LLC significantly increased its stake in Amgen Inc. by 28.1% in the fourth quarter, bringing their total holdings to $37.88 million. Amgen also reported strong fourth-quarter earnings, beating analyst expectations, and announced a quarterly dividend of $2.52 per share. The stock currently holds a "Hold" rating from analysts with a consensus price target of $354.60.
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026 - News and Statistics
Amidst growing recession fears and a volatile market, investors are seeking stability, leading to a focus on healthcare sector stocks like AbbVie and Amgen. AbbVie, a pharmaceutical company with strong portfolios in immunology, oncology, and neuroscience, is considered a safe bet due to its critical treatments and status as a Dividend King. Amgen, despite recent patent expirations, maintains business stability with a broad portfolio and promising pipeline, making both companies attractive for risk-averse investors.
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer
Zai Lab Limited and Amgen Inc. have announced a global clinical trial collaboration to evaluate a DLL3-targeting combination therapy for extensive-stage small cell lung cancer (ES-SCLC). Amgen will sponsor a global Phase 1b study to test Zai Lab's investigational ADC, zocilurtatug pelitecan (zoci), in combination with Amgen’s IMDELLTRA®, a DLL3-targeting Bispecific T-cell Engager. Zai Lab will retain full ownership of zoci, which has shown a high response rate in previous trials for heavily pretreated SCLC patients.
Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study
Amgen Inc. (AMGN) has announced a new Phase 2, open-label rollover study for its drug AMG 732, targeting patients with Thyroid Eye Disease (TED) who previously did not respond to treatment or relapsed. This study focuses on tougher cases to gather relevant real-world data on the drug's efficacy and safety for individuals with high unmet needs. Amgen's move indicates a strategy to solidify its position in the TED market by addressing difficult-to-treat patient populations, which could lead to a broader drug label and positive investor sentiment.
Amgen Beats Estimates by $400 Million in Q4: Here’s Why Analysts Target $350
Amgen (AMGN) reported strong Q4 2025 revenues, beating consensus estimates by $400 million, driven by the robust growth of key products like Repatha, EVENITY, and TEZSPIRE. Despite potential biosimilar headwinds, the company provided optimistic 2026 guidance and is expanding its pipeline with promising cardiometabolic and obesity therapies. Analysts have a mixed view, with a mean price target of $350.55, but TIKR's valuation model suggests a higher mid-case target of $459.52 by 2030, indicating the stock is undervalued relative to its growth trajectory.
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
Regeneron Pharmaceuticals (NASDAQ: REGN) is undergoing a significant transformation, moving beyond its core immunology and ophthalmology franchises to aggressively enter the oncology and obesity markets. The company, known for its science-first approach and internal innovation, is navigating the challenges of biosimilar competition and shifting regulatory landscapes while leveraging its robust R&D and strong balance sheet for future growth. Key catalysts include upcoming data readouts for Fianlimab in oncology and advancements in its obesity and gene therapy programs.
Dorato Capital Management Invests $1.58 Million in Amgen Inc. $AMGN
Dorato Capital Management has acquired a new position in Amgen Inc. (NASDAQ:AMGN), purchasing 4,799 shares valued at approximately $1.58 million, making it their 21st-largest holding. Amgen recently reported strong Q4 earnings, surpassing analyst estimates for both EPS and revenue, and has issued optimistic FY2026 guidance. Despite mixed analyst sentiment, with an average "Hold" rating, several price targets have been increased, and the company has declared a quarterly dividend of $2.52 per share.
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry
This article compares Apellis Pharmaceuticals (NASDAQ: APLS) with its biotechnology industry peers, analyzing financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. While Apellis shows potential undervaluation based on its P/S ratio, other indicators suggest overvaluation and weaker financial performance, including a high debt-to-equity ratio, compared to its competitors. The analysis aims to provide investors with insights into the company's standing within the competitive biotechnology sector.
Aberdeen Group plc Acquires 27,107 Shares of Amgen Inc. $AMGN
Aberdeen Group plc increased its stake in Amgen Inc. by 4.5% during the fourth quarter, purchasing 27,107 additional shares to bring its total holding to 629,646 shares valued at approximately $206.09 million. Amgen reported strong Q4 earnings, beating analyst expectations with $5.29 EPS and $9.87 billion in revenue, and provided optimistic guidance for FY2026. The company also announced a quarterly dividend of $2.52 per share, and analysts currently have an average "Hold" rating on the stock with a target price of $354.60.
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer
Zai Lab Limited and Amgen Inc. have announced a global clinical trial collaboration to evaluate a novel DLL3-targeting combination therapy for extensive-stage small cell lung cancer (ES-SCLC). Amgen will lead a Phase 1b study combining Zai Lab's zocilurtatug pelitecan (an ADC) with Amgen's IMDELLTRA (a BiTE therapy), aiming to improve treatment response and overcome resistance. Zai Lab will maintain full ownership of its ADC, which has shown promising activity, including intracranial efficacy, in previous trials.
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer
Zai Lab Limited and Amgen Inc. have announced a global clinical trial collaboration to assess a DLL3-targeting combination therapy for extensive-stage small cell lung cancer (ES-SCLC). The collaboration will evaluate Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan, with Amgen’s bispecific T-cell engager (BiTE) therapy, IMDELLTRA. Amgen will lead a global Phase 1b study to determine the safety and efficacy of this combined approach, aiming to improve treatment response and overcome resistance in ES-SCLC patients.
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now?
Amgen Inc. (AMGN) is highlighted as a top pharma stock after recent positive clinical trial results for Repatha® and strong financial performance in fiscal year 2025 with double-digit revenue and EPS growth. The company, a biotechnology firm specializing in human therapeutics for complex cancers, is presented as a strong investment. However, the article also subtly pivots to suggest that certain AI stocks might offer even greater returns and urges readers to consider a different "cheapest AI stock" with significant upside potential.
Turning Up the Volume on IgG4-RD Awareness and Diagnosis
This article highlights the challenges of diagnosing IgG4-RD, a rare disease known as "the great mimicker" due to its varied symptoms. It emphasizes the critical need for increased awareness, multidisciplinary care, and collaborative efforts among patient advocacy groups and healthcare providers to facilitate earlier diagnosis. The story of Andy Provencher, misdiagnosed for months, underscores the importance of such collaboration for patients and their families.
Novartis AG (ADR) Stock: Resilient Pharma Leader with Strong Fundamentals and Growth Potential for North American Investors
This article provides an in-depth analysis of Novartis AG (ADR) for North American investors, highlighting its resilient position as a pharma leader with strong fundamentals and growth potential. It details the company's business model focused on innovation, key products in high-demand therapeutic areas, and its robust market position. The report also addresses sector drivers, competitive landscape, risks, and what investors should monitor going forward.
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR)
This article provides a detailed overview of Monopar Therapeutics Inc (NASDAQ: MNPR) stock, including its current price, performance, key statistics, and technical and fundamental analysis ratings from ChartMill. It also covers earnings, analyst forecasts, financial highlights, ownership details, and a company profile outlining its biopharmaceutical focus on cancer treatments.
HF Advisory Group LLC Buys 7,548 Shares of Amgen Inc. $AMGN
HF Advisory Group LLC significantly increased its stake in Amgen Inc. by 341.8% in Q4, purchasing an additional 7,548 shares to reach a total of 9,756 shares valued at approximately $3.19 million. Amgen exceeded Q4 earnings and revenue estimates and provided FY2026 guidance, yet it faces rising regulatory and competitive challenges, including FDA warnings regarding its drug Tavneos and increased biosimilar competition. Analysts currently maintain a "Hold" consensus rating for Amgen with an average price target of $354.60.
HF Advisory Group LLC Buys 13,212 Shares of Gilead Sciences, Inc. $GILD
HF Advisory Group LLC increased its stake in Gilead Sciences, Inc. by 66.5%, purchasing an additional 13,212 shares, bringing their total ownership to 33,076 shares valued at $4.06 million. Institutional investors now hold approximately 83.67% of the company's stock, reflecting strong confidence. Analysts rate Gilead as a "Moderate Buy" with a consensus price target of $157.62, following a Q4 earnings beat and a raised quarterly dividend to $0.82.
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030
The pediatric neuroblastoma treatment market is experiencing substantial growth, projected to reach $3.13 billion by 2030 from $2.02 billion in 2025, driven by enhanced R&D in targeted therapies, increased use of CAR T-cell and monoclonal antibodies, and personalized medicine. Key drivers include a rising number of neuroblastoma cases globally and advancements in diagnostic and screening technologies. Leading companies like United Therapeutics and Pfizer are innovating with antibody-based approaches, and North America currently leads the market.
Does Alvotech’s (ALVO) Reaffirmed 2026 Revenue Target Redefine Its Biosimilar Strategy Narrative?
Alvotech has reaffirmed its 2026 revenue guidance of US$650 million to US$700 million, alongside detailing five approved biosimilar products and nine additional candidates in its pipeline. This update highlights the company's focus on cash flow and margin expansion through sales growth and operational efficiencies, strengthening its investment narrative. While the expanded biosimilar reach and partnerships are crucial for offsetting milestone revenues, investors should consider the risks posed by regulatory timing, pricing pressure, and a leveraged balance sheet.
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy
Zai Lab announced a global clinical research collaboration with Amgen to investigate a novel combination therapy for extensive-stage small cell lung cancer (ES-SCLC). The collaboration will evaluate Zai Lab's Zocilurtatug Pelitecan (Zoci), a DLL3-targeted antibody-drug conjugate, with Amgen's IMDELLTRA? (tarlatamab), a DLL3-targeted bispecific T-cell engager. Amgen will sponsor a Phase 1b study, with Zai Lab retaining full ownership of Zoci and supplying the drug.
Allogene Therapeutics Stock Gains Momentum from Sector Tailwinds ()
Allogene Therapeutics is experiencing a surge in stock value due to a positive shift in the biotechnology sector, driven by strategic acquisitions and licensing deals. The cell therapy specialist's clinical pipeline is attracting institutional investors, pushing its stock close to its yearly peak with an approximately 96% gain since the start of the year. Future growth hinges on concrete data readouts from its research pipeline and further industry consolidation.
Amgen Leads Trading Activity Following Cancer Drug Partnership with Zai Lab
Amgen led trading activity with a slight stock increase and significant volume, driven by a new partnership with Zai Lab. This collaboration aims to advance treatments for extensive-stage small cell lung cancer (ES-SCLC) by combining Zai Lab’s DLL3-targeting antibody-drug conjugate with Amgen’s bispecific T-cell engager. The partnership leverages both companies' expertise to address critical unmet needs in cancer therapy, with Zai Lab's stock showing a positive market response.
Will FDA Tavneos Safety Scrutiny and New Lung Cancer Combo Trial Change Amgen's (AMGN) Narrative?
Amgen faces scrutiny from the FDA regarding dozens of Tavneos-linked liver injury cases, including severe events and deaths, which could impact its regulatory risk profile. Concurrently, Amgen is collaborating with Zai Lab on a Phase 1b trial for small cell lung cancer, highlighting its continued investment in high-risk oncology programs. Investors are advised to consider the potential Tavneos safety overhang as it could reshape Amgen's investment narrative, despite the company's diversified portfolio and attractive dividend.
Amgen Inc. Stock: Biotech Leader's Strategic Pipeline and Oncology Focus Drive Long-Term Investor Va
Amgen Inc. is highlighted as a strong biotechnology company with a robust pipeline, particularly in oncology, and a focus on innovative therapies. The article emphasizes Amgen's stable financial health, consistent dividend payouts, and strategic R&D investments, making it an attractive option for North American investors seeking growth and income. It also discusses the company's core business model, key products driving revenue, and risks associated with biotech stocks.
